Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.43 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.32 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26206455 | 0.91 | TMPRSS2 (0.46) | TMPRSS2RIPK1 | |
| SCHEMBL26206193 | 0.90 | TMPRSS2 (0.48) | TMPRSS2RIPK1 | |
| SCHEMBL26206222 | 0.88 | TMPRSS2 (0.46) | TMPRSS2RIPK1 | |
| SCHEMBL25381503 | 0.88 | TMPRSS2 (0.49) | TMPRSS2RIPK1 | |
| SCHEMBL26399124 | 0.87 | TMPRSS2 (0.35) | TMPRSS2RIPK1 | |
| SCHEMBL25432619 | 0.86 | TMPRSS2 (0.51) | TMPRSS2RIPK1 | |
| SCHEMBL25379160 | 0.86 | TMPRSS2 (0.51) | TMPRSS2RIPK1 | |
| SCHEMBL26328814 | 0.86 | TMPRSS2 (0.31) | TMPRSS2SLC5A1SLC5A2ADORA2AADORA2B | |
| SCHEMBL25433905 | 0.86 | TMPRSS2 (0.48) | TMPRSS2RIPK1 | |
| SCHEMBL25383499 | 0.86 | TMPRSS2 (0.48) | TMPRSS2RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12448383-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250197410-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2025-06-19 | — | — | US | disclosed |
| US-12180217-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-20240246986-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2024-07-25 | — | — | US | disclosed |
| US-20240150359-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2024-05-09 | — | — | US | disclosed |
| EP-4320128-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-11851438-B2 | 1′-cyano nucleoside analogs and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-11845755-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-11780844-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780844-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230279015-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279015-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279015-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279013-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279013-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279013-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| WO-2023167944-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023167944-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-20230279014-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279014-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780844-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | TMPRSS2 112/4885SLC5A1 1689/4885SLC5A2 1707/4885 |
| US-20240150359-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | TMPRSS2 112/4885SLC5A1 1689/4885SLC5A2 1707/4885 |
| US-20230279015-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | TMPRSS2 112/4885SLC5A1 1689/4885SLC5A2 1707/4885 |
| US-12180217-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | TMPRSS2 112/4885SLC5A1 1689/4885SLC5A2 1707/4885 |
| US-20230279014-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | TMPRSS2 112/4885SLC5A1 1689/4885SLC5A2 1707/4885 |
| US-20240246986-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | TMPRSS2 112/4885SLC5A1 1689/4885SLC5A2 1707/4885 |
| US-12448383-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | TMPRSS2 112/4885SLC5A1 1689/4885SLC5A2 1707/4885 |
| US-11851438-B2 | 1′-cyano nucleoside analogs and methods for treatment of viral infections | TYMP, PNP, SAMHD1 | TMPRSS2 2073/4885SLC5A1 165/4885SLC5A2 655/4885 |
| US-20230279013-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | TMPRSS2 112/4885SLC5A1 1689/4885SLC5A2 1707/4885 |
| US-11845755-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | TMPRSS2 112/4885SLC5A1 1689/4885SLC5A2 1707/4885 |
| US-20250197410-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | TMPRSS2 112/4885SLC5A1 1689/4885SLC5A2 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.